• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过支架跳跃策略发现靶向慢性髓性白血病中 Hsp70-Bim 蛋白-蛋白相互作用的联苯衍生物。

Discovery of Biphenyl Derivatives to Target Hsp70-Bim Protein-Protein Interaction in Chronic Myeloid Leukemia by Scaffold Hopping Strategy.

机构信息

Cancer Hospital of Dalian University of Technology, School of Chemistry, Dalian University of Technology, Dalian, Liaoning 116024, China.

Department of Hematology, Central Hospital of Dalian University of Technology, Dalian University of Technology, Dalian, Liaoning 116024, China.

出版信息

J Med Chem. 2024 Jul 25;67(14):12068-12084. doi: 10.1021/acs.jmedchem.4c00780. Epub 2024 Jul 16.

DOI:10.1021/acs.jmedchem.4c00780
PMID:39012838
Abstract

Hsp70-Bim protein-protein interaction (PPI) is the most recently identified specific target in chronic myeloid leukemia (CML) therapy. Herein, we developed a new class of Hsp70-Bim PPI inhibitors via scaffold hopping of , the most potent Hsp70-Bim PPI inhibitor thus far. Through structure-activity relationship (SAR) study, we obtained a biphenyl scaffold compound with a 5.6-fold improvement in Hsp70-Bim PPI suppression ( = 123 vs 688 nM) and a 4-fold improvement in water solubility (29.42 vs 7.19 μg/mL) compared to . It maintains comparable apoptosis induction capability with against both TKI-sensitive and TKI-resistant CML cell lines in an Hsp70-Bim-dependent manner. Additionally, through SAR, H-N TRSOY-NMR, and molecular docking, we revealed that Lys319 is a "hot spot" in the Hsp70-Bim PPI interface. Collectively, these results provide a novel chemical scaffold and structural insights for the rational design of Hsp70-Bim PPI inhibitors.

摘要

热休克蛋白 70- Bim 蛋白-蛋白相互作用(PPI)是慢性髓系白血病(CML)治疗中最近确定的特定靶点。在此,我们通过 的骨架跃迁开发了一类新型热休克蛋白 70-Bim PPI 抑制剂,这是迄今为止最有效的热休克蛋白 70-Bim PPI 抑制剂。通过构效关系(SAR)研究,我们获得了一种联苯骨架化合物 ,与 相比,其对热休克蛋白 70-Bim PPI 的抑制作用提高了 5.6 倍( = 123 对 688 nM),水溶性提高了 4 倍(29.42 对 7.19 μg/mL)。与 相比,它以热休克蛋白 70-Bim 依赖的方式保持了对 TKI 敏感和 TKI 耐药 CML 细胞系类似的凋亡诱导能力。此外,通过 SAR、H-N TRSOY-NMR 和分子对接,我们揭示了 Lys319 是热休克蛋白 70-Bim PPI 界面的“热点”。总之,这些结果为热休克蛋白 70-Bim PPI 抑制剂的合理设计提供了新的化学骨架和结构见解。

相似文献

1
Discovery of Biphenyl Derivatives to Target Hsp70-Bim Protein-Protein Interaction in Chronic Myeloid Leukemia by Scaffold Hopping Strategy.通过支架跳跃策略发现靶向慢性髓性白血病中 Hsp70-Bim 蛋白-蛋白相互作用的联苯衍生物。
J Med Chem. 2024 Jul 25;67(14):12068-12084. doi: 10.1021/acs.jmedchem.4c00780. Epub 2024 Jul 16.
2
Small-molecule inhibitor targeting the Hsp70-Bim protein-protein interaction in CML cells overcomes BCR-ABL-independent TKI resistance.小分子抑制剂靶向 CML 细胞中的 Hsp70-Bim 蛋白-蛋白相互作用,克服了 BCR-ABL 独立的 TKI 耐药性。
Leukemia. 2021 Oct;35(10):2862-2874. doi: 10.1038/s41375-021-01283-5. Epub 2021 May 18.
3
A kinase-independent Bcr-Abl function mediating an Hsp70-Bim protein-protein interaction in chronic myeloid leukemia.一种不依赖激酶的Bcr-Abl功能介导慢性粒细胞白血病中Hsp70与Bim的蛋白质-蛋白质相互作用。
Int J Biol Macromol. 2025 May;310(Pt 3):143249. doi: 10.1016/j.ijbiomac.2025.143249. Epub 2025 Apr 16.
4
Exploiting the "Hot-Spots" of Hsp70Bim ProteinProtein Interaction to Optimize the 1-Oxo-1-phenalene-2,3-dicarbonitrile Analogues as Specific Hsp70Bim Inhibitors.利用热休克蛋白 70(Hsp70)Bim 蛋白-蛋白相互作用的“热点”优化 1-氧代-1-苯并[C]菲-2,3-二腈类似物作为特异性 Hsp70Bim 抑制剂。
J Med Chem. 2023 Dec 14;66(23):16377-16387. doi: 10.1021/acs.jmedchem.3c01783. Epub 2023 Nov 27.
5
A novel Hsp70 inhibitor specifically targeting the cancer-related Hsp70-Bim protein-protein interaction.一种新型 Hsp70 抑制剂,特异性靶向与癌症相关的 Hsp70-Bim 蛋白-蛋白相互作用。
Eur J Med Chem. 2021 Aug 5;220:113452. doi: 10.1016/j.ejmech.2021.113452. Epub 2021 Apr 14.
6
Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic.Bim和Bad介导伊马替尼诱导的Bcr/Abl+白血病细胞杀伤,因它们缺失导致的耐药性可被一种BH3模拟物克服。
Proc Natl Acad Sci U S A. 2006 Oct 3;103(40):14907-12. doi: 10.1073/pnas.0606176103. Epub 2006 Sep 22.
7
Bcr-Abl drives the formation of Hsp70/Bim PPI to stabilize oncogenic clients and prevent cells from undergoing apoptosis.Bcr-Abl驱动Hsp70/Bim蛋白-蛋白相互作用的形成,以稳定致癌性客户蛋白并防止细胞发生凋亡。
Biochem Pharmacol. 2022 Apr;198:114964. doi: 10.1016/j.bcp.2022.114964. Epub 2022 Feb 16.
8
Exploring the binding mechanism of a small molecular Hsp70-Bim PPI inhibitor through molecular dynamic simulation.通过分子动力学模拟探索小分子 Hsp70-Bim PPI 抑制剂的结合机制。
J Mol Model. 2024 Feb 13;30(3):71. doi: 10.1007/s00894-024-05874-8.
9
Rationally designed BCR-ABL kinase inhibitors for improved leukemia treatment via covalent and pro-/dual-drug targeting strategies.通过共价和前药/双药靶向策略合理设计的用于改善白血病治疗的BCR-ABL激酶抑制剂。
J Adv Res. 2025 Aug;74:541-554. doi: 10.1016/j.jare.2024.09.008. Epub 2024 Sep 8.
10
In silico design and computational evaluation of novel 2-arylaminopyrimidine-based compounds as potential multi-targeted protein kinase inhibitors: application for the native and mutant (T315I) Bcr-Abl tyrosine kinase.基于 2-芳基氨基嘧啶的新型化合物的计算机设计与计算评估:作为潜在多靶点蛋白激酶抑制剂的应用,针对天然和突变(T315I)Bcr-Abl 酪氨酸激酶。
J Biomol Struct Dyn. 2023 Jun;41(9):4065-4080. doi: 10.1080/07391102.2022.2062784. Epub 2022 Apr 26.